Compare NMAI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMAI | VALN |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | NMAI | VALN |
|---|---|---|
| Price | $14.50 | $6.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 87.3K | 78.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | $22.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $4.75 |
| 52 Week High | $15.06 | $12.23 |
| Indicator | NMAI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 66.26 |
| Support Level | $13.48 | $5.03 |
| Resistance Level | $15.06 | $7.31 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 54.56 | 59.80 |
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.